2020 Annual Meeting | C146 - Multiple Sclerosis Overview 1: Clinical Pearls

Date Tuesday 04/28/20

Time 01:00 PM - 03:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Mary A. Willis, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants should become more familiar with diagnosis and treatment of multiple sclerosis and related conditions, including use of recently approved therapies.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
01:00 PM - 01:10 PM	Introduction	Introduction Mary A. Willis, MD, FAAN
01:10 PM - 01:40 PM	Speaker	Applying Diagnostic Criteria for MS and Watching for Pitfalls Mary A. Willis, MD, FAAN
01:40 PM - 02:10 PM	Speaker	Management of Relapsing Remitting MS Enrique Alvarez, MD, PhD
02:10 PM - 02:40 PM	Speaker	Management of Progressive MS Marisa P. McGinley, DO
02:40 PM - 03:00 PM	Q&A	Ask the Panel: Diagnostic and Treatment Dilemmas in Your Practice

Faculty Disclosures
Enrique Alvarez, MD, PhD	Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Alvarez has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene/BMS. The institution of an immediate family member of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon.
Mary A. Willis, MD, FAAN	Dr. Willis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion, Biogen. Dr. Willis has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion, Biogen.
Marisa P. McGinley, DO	Dr. McGinley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. McGinley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. McGinley has received research support from Biogen. The institution of Dr. McGinley has received research support from Genentech. The institution of Dr. McGinley has received research support from NIH. The institution of Dr. McGinley has received research support from AHRQ.

��ɫ��

��ɫ��